SciSparc (SPRC) Competitors $0.21 0.00 (-0.19%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SPRC vs. CYCN, RDHL, BCDA, MYNZ, VCNX, MBIO, GNPX, BCLI, ENSC, and VIRXShould you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Cyclerion Therapeutics (CYCN), RedHill Biopharma (RDHL), BioCardia (BCDA), Mainz Biomed (MYNZ), Vaccinex (VCNX), Mustang Bio (MBIO), Genprex (GNPX), Brainstorm Cell Therapeutics (BCLI), Ensysce Biosciences (ENSC), and Viracta Therapeutics (VIRX). These companies are all part of the "pharmaceutical products" industry. SciSparc vs. Cyclerion Therapeutics RedHill Biopharma BioCardia Mainz Biomed Vaccinex Mustang Bio Genprex Brainstorm Cell Therapeutics Ensysce Biosciences Viracta Therapeutics SciSparc (NASDAQ:SPRC) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk. Which has more risk & volatility, SPRC or CYCN? SciSparc has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Is SPRC or CYCN more profitable? SciSparc's return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SciSparcN/A N/A N/A Cyclerion Therapeutics N/A -55.32%-48.35% Does the MarketBeat Community favor SPRC or CYCN? Cyclerion Therapeutics received 32 more outperform votes than SciSparc when rated by MarketBeat users. However, 66.67% of users gave SciSparc an outperform vote while only 58.62% of users gave Cyclerion Therapeutics an outperform vote. CompanyUnderperformOutperformSciSparcOutperform Votes266.67% Underperform Votes133.33% Cyclerion TherapeuticsOutperform Votes3458.62% Underperform Votes2441.38% Do insiders & institutionals believe in SPRC or CYCN? 25.1% of SciSparc shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 1.5% of SciSparc shares are owned by insiders. Comparatively, 36.1% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has higher earnings and valuation, SPRC or CYCN? SciSparc has higher revenue and earnings than Cyclerion Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSciSparc$1.75M1.26-$5.12MN/AN/ACyclerion Therapeutics$194K44.56-$5.26MN/AN/A Does the media favor SPRC or CYCN? In the previous week, Cyclerion Therapeutics had 1 more articles in the media than SciSparc. MarketBeat recorded 3 mentions for Cyclerion Therapeutics and 2 mentions for SciSparc. SciSparc's average media sentiment score of 1.00 beat Cyclerion Therapeutics' score of 0.00 indicating that SciSparc is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SciSparc 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cyclerion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySciSparc and Cyclerion Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get SciSparc News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRC vs. The Competition Export to ExcelMetricSciSparcPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.21M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5990.0517.20Price / Sales1.26196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book0.025.094.784.78Net Income-$5.12M$151.83M$120.31M$225.60M7 Day Performance-21.35%-2.14%-1.92%-1.23%1 Month Performance-13.05%-4.56%13.65%0.46%1 Year Performance-95.51%8.87%28.34%15.24% SciSparc Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRCSciSparc0.9834 of 5 stars$0.21-0.2%N/A-95.6%$2.21M$1.75M0.004Gap UpCYCNCyclerion Therapeutics0.6362 of 5 stars$3.52+2.6%N/A-22.2%$9.54M$194,000.000.0030Gap DownRDHLRedHill Biopharma0.4365 of 5 stars$7.41-0.4%N/A-99.2%$9.49M$3.71M0.00210Gap DownBCDABioCardia3.3021 of 5 stars$2.03-2.4%$25.00+1,131.5%-79.8%$9.31M$71,000.00-0.5016Analyst ForecastShort Interest ↓Positive NewsGap UpMYNZMainz Biomed2.5033 of 5 stars$4.61-14.0%$120.00+2,503.0%-85.7%$9.23M$917,203.00-0.0730News CoverageGap UpHigh Trading VolumeVCNXVaccinex0.9775 of 5 stars$3.54-4.1%N/A-85.7%$9.20M$570,000.00-0.0840Positive NewsMBIOMustang Bio1.9623 of 5 stars$0.19-0.5%$2.00+939.5%-86.3%$9.19MN/A-0.12100Positive NewsGNPXGenprex3.9233 of 5 stars$1.04-10.8%$10.00+866.2%-89.1%$8.81MN/A0.0020Gap UpBCLIBrainstorm Cell Therapeutics3.9873 of 5 stars$1.54+5.9%$30.00+1,854.4%-21.2%$8.75MN/A-0.3040Gap UpENSCEnsysce Biosciences0.0873 of 5 stars$6.69+19.0%N/A-49.1%$8.74M$2.23M-0.2010VIRXViracta Therapeutics2.5296 of 5 stars$0.22+7.5%$5.00+2,193.6%-56.7%$8.66MN/A-0.1820Gap Down Related Companies and Tools Related Companies CYCN Alternatives RDHL Alternatives BCDA Alternatives MYNZ Alternatives VCNX Alternatives MBIO Alternatives GNPX Alternatives BCLI Alternatives ENSC Alternatives VIRX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SPRC) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
